%0 Journal Article
%T Biological therapies in systemic lupus erythematosus
%A Dorota Suszek
%A Rados£¿aw Jeleniewicz
%A Maria Majdan
%J Post£¿py Higieny i Medycyny Do£¿wiadczalnej
%D 2012
%I Index Copernicus International S.A.
%X The prevention of chronic organic damage and complete inhibition of inflammatory activity of the disease are the main goals in the treatment of systemic lupus erythematosus (SLE). Current therapies of SLE are not effective enough and they may cause various serious side effects. Biological therapies, affecting important pathogenetic disturbances in the immunological system of SLE patients, give hope for the development of a new treatment for SLE. Currently the most advanced clinical trials are being conducted with anti-lymphocyte B drugs, such as rituximab, belimumab and epratuzumab. Belimumab as the first biological agent was registered for treatment of the active, seropositive form of SLE. The advances in immunology and rheumatology nowadays raise the hope of finding effective and safe treatment for SLE. In our article we present an overview of data concerning perspectives of biological treatment in SLE.
%K systemic lupus erythematosus
%K Biological treatment
%K tocze¨½ rumieniowaty uk adowy
%K leczenie biologiczne
%U http://journals.indexcopernicus.com/fulltxt.php?ICID=1007663